Head to Head Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) versus Unicycive Therapeutics (NASDAQ:UNCY)
by Danessa Lincoln · The Markets DailyTeva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Valuation and Earnings
This table compares Teva Pharmaceutical Industries and Unicycive Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Teva Pharmaceutical Industries | $17.26 billion | 2.96 | $1.41 billion | $0.43 | 101.92 |
| Unicycive Therapeutics | N/A | N/A | -$26.56 million | ($1.75) | -2.07 |
Teva Pharmaceutical Industries has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Teva Pharmaceutical Industries has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.
Profitability
This table compares Teva Pharmaceutical Industries and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Teva Pharmaceutical Industries | 2.94% | 33.20% | 6.59% |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Teva Pharmaceutical Industries and Unicycive Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Teva Pharmaceutical Industries | 1 | 1 | 13 | 0 | 2.80 |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Teva Pharmaceutical Industries currently has a consensus price target of $48.15, indicating a potential upside of 9.88%. Unicycive Therapeutics has a consensus price target of $18.25, indicating a potential upside of 403.31%. Given Unicycive Therapeutics’ higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Teva Pharmaceutical Industries.
Summary
Teva Pharmaceutical Industries beats Unicycive Therapeutics on 10 of the 13 factors compared between the two stocks.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
About Unicycive Therapeutics
Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.